Treatment of inflammatory myopathies
- PMID: 16822917
- PMCID: PMC2563757
- DOI: 10.1136/pgmj.2005.038455
Treatment of inflammatory myopathies
Abstract
Idiopathic inflammatory myopathies, notably polymyositis and dermatomyositis are comparatively uncommon diseases and few randomised, double blind placebo controlled trials have been done. Final validation of measures to assess outcome and response to treatment is awaited. Corticosteroids are an effective initial treatment, although rarely tested in randomised controlled trials. Unfortunately, not all patients respond to them and many develop undesirable side effects. There is thus a need for second line agents notably immunosuppressives or intravenous immunoglobulin. There are no defined guidelines or best treatment protocols agreed internationally and so the medical approach must be individualised, based on the severity of clinical presentation, disease duration, presence of extramuscular features, and prior therapy and contraindications to particular agents. There is still a significant percentage of non-responders (around 25%) and clinical relapses. Novel therapeutic approaches are now directed towards cytokine modulation and the use of monoclonal antibodies targeting B and T cells.
Conflict of interest statement
Conflicts of interest: none declared.
Similar articles
-
Idiopathic inflammatory myopathies: current and future therapeutic options.Neurotherapeutics. 2008 Oct;5(4):548-57. doi: 10.1016/j.nurt.2008.08.008. Neurotherapeutics. 2008. PMID: 19019306 Free PMC article. Review.
-
Treatment of idiopathic inflammatory myopathies.Curr Opin Neurol. 2003 Oct;16(5):569-75. doi: 10.1097/01.wco.0000093099.34793.40. Curr Opin Neurol. 2003. PMID: 14501840 Review.
-
Therapeutic options in autoimmune inflammatory myopathies (dermatomyositis, polymyositis, inclusion body myositis).J Neurol. 2006 Sep;253 Suppl 5:V64-5. doi: 10.1007/s00415-006-5010-2. J Neurol. 2006. PMID: 16998756 Review.
-
Current approach to the treatment of polymyositis and dermatomyositis.Curr Opin Rheumatol. 2000 Nov;12(6):492-7. doi: 10.1097/00002281-200011000-00003. Curr Opin Rheumatol. 2000. PMID: 11092197 Review.
-
Current treatment of the inflammatory myopathies.Curr Opin Rheumatol. 1994 Nov;6(6):595-601. doi: 10.1097/00002281-199411000-00008. Curr Opin Rheumatol. 1994. PMID: 7865379 Review.
Cited by
-
Unveiling the Rare Complication: Statin-Induced Immune-Mediated Necrotizing Myopathy.Am J Case Rep. 2023 Dec 13;24:e941387. doi: 10.12659/AJCR.941387. Am J Case Rep. 2023. PMID: 38087774 Free PMC article.
-
Rituximab in myositis: where are we now? A survey of current usage.Rheumatology (Oxford). 2023 Jul 5;62(7):e211-e212. doi: 10.1093/rheumatology/kead010. Rheumatology (Oxford). 2023. PMID: 36622027 Free PMC article. No abstract available.
-
A rare case of NXP-2 positive dermatomyositis.Arch Clin Cases. 2021 Oct 27;7(4):68-71. doi: 10.22551/2020.29.0704.10176. eCollection 2020. Arch Clin Cases. 2021. PMID: 34754931 Free PMC article.
-
COVID-19 IgG-related autoimmune inflammatory necrotizing myositis.BMJ Case Rep. 2021 Apr 13;14(4):e239457. doi: 10.1136/bcr-2020-239457. BMJ Case Rep. 2021. PMID: 33849864 Free PMC article.
-
Breast cancer and dermatomyositis: a case study and literature review.Curr Oncol. 2017 Oct;24(5):e429-e433. doi: 10.3747/co.24.3696. Epub 2017 Oct 25. Curr Oncol. 2017. PMID: 29089813 Free PMC article.
References
-
- Isenberg D A, Ramsey‐Goldman R. Assessing patients with lupus: towards a drug responder index. Rheumatology 1999381045–1049. - PubMed
-
- Choy E H S, Isenberg D A. Treatment of dermatomyositis and polymyositis. Rheumatology 2002417–13. - PubMed
-
- Dalakas M. Polymyositis and dermatomyositis. Lancet 2003362971–982. - PubMed
-
- Oddis C. Idiopathic inflammatory myopathies: a treatment update. Curr Rheumatol Rep 20035431–436. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical